Next Generation of Topical Ophthalmic Treatments

Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients.

Oculis' novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.

The Company's leading clinical candidates are:

- OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone based on Oculis' proprietary Solubilizing Nanoparticle (SNP) technology.

- OCS-02 is a novel topical anti-TNF alpha antibody.

In addition, Oculis' formulation discovery focus and capabilities are enabling the development of topical drugs targeting sight-threatening diseases.